Pfizer to Slash 30% of its Sales & Marketing Staff
Pfizer Inc. may slash its 38,000-member sales and marketing staff by as much as 30%, or 11,400 employees.
Pfizer Inc., the world's biggest drugmaker, may cut as much as 30 percent of...
It’s the land of success!
Big Pharma had a plan.
It designed a trial for a COX-2 drug and it ran.
Yet it wasn’t enough to get pain low.
What's this?
We’re still here in the land of no? ...
Buzz is NOT regulated by FDA
It seems that Cialis will be back at the Super Bowl with a 60-second commercial that may cost as much as $4.8 million (see "Impotence drug returns to Super Bowl ...
Can Drug Ads Communicate Risk?
Bob Erlich of DTC Perspectives magazine said in a recent newsletter:
"Drug makers ... need to be totally upfront about risk, educating consumers in understandable language on the odds of a serious...
DTC in 2005: Old Dogs, New Tricks?
Based on results from the "2004 DTC Industry Checkup" -- a survey of DTC (direct-to-consumer) drug marketers by Optas, Inc. and DTC Perspectives, Inc. -- a majority of marketers expect DTC...
Pharmaceutical PR: Fool Me Once, Fool Me Twice
Well, the elections are over and the industry's best boy -- G. W. Bush -- and Republican congressional cronies are in place and eager to spend the "political capital" gained. Without...
Marketing Drugs Like Packaged Goods at the Super Bowl
At the last Super Bowl a brouhaha arose over the half-time show. It also brought some unwelcome attention to direct-to-consumer (DTC) advertising. A Comedy Central skit after the game, for instance,...
Pharma Profits on Slippery Slope?
Some fourth quarter data are in from the pharmaceutical industry and, on the surface, it looks good for profits:
Pfizer said it earned $4.39 billion, or 58 cents a share, in the...
Drug Prices/Declining Profits Top Issues for 2005
According to results of the recent Pharma Marketing News 2005 HOT ISSUE survey, drug prices, declining profits, and dwindling pipeline of new drugs are the top issues that will have the...
How the FDA Can Fix DTC
According to today's Financial Times (FT), executives from UK pharma companies GlaxoSmithKline and AstraZeneca told a UK parliamentary committee they did not believe it was appropriate (my emphasis) for Britain to...
